Answers are grounded in this paper and cite their sources.
The 2012 scaling back of limits on FDA advisory panel financial conflicts had no clear basis and may have unanticipated impacts.
No takes yet. Share an insight, caveat, or question.
Wood et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: